Design Pharmaceuticals utilizes ultra-high throughput bioscience technologies to conduct multiplex GPCR screening, enabling the rapid identification of drug candidates from diverse ligand libraries. This approach addresses the urgent need for effective treatments for diseases lacking satisfactory therapies by providing high-quality data at unprecedented scale and speed.
Funding
$14.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases lack effective treatments due to the challenges in identifying drug candidates that target G protein-coupled receptors (GPCRs). Traditional GPCR screening methods often struggle to provide the scale and speed needed to explore diverse ligand libraries effectively.
Solution
Design Pharmaceuticals utilizes ultra-high throughput bioscience technologies to accelerate GPCR drug discovery. Their platform enables the rapid screening of diverse ligand libraries, including small molecules, antibodies/nanobodies, and peptides/hormones, against multiple GPCR assay formats such as cell-based agonist and antagonist assays. By multiplexing GPCR readouts, the platform generates extensive data for computational and experimental drug design, facilitating the development of breakthrough therapeutics. The technology allows for scalable and flexible interrogation of GPCR signaling, delivering high-quality data with industry-leading throughput.
Target Audience
The primary customers are research and development teams in the pharmaceutical industry focused on discovering and developing therapeutics targeting GPCRs.
Features
- Ultra-high throughput screening of GPCRs using droplet-based technology at a scale of 10^8 droplets per week for a single GPCR.
- Automated multiplex screening at a scale of 10^4 per week.
- Capability to screen all GPCR ligand library types, including small molecules, antibodies/nanobodies, and peptides/hormones.
- Supports multiple GPCR assay formats, including cell-based agonist and antagonist assays.
- Enables live cell functional screening in millions of parallel droplet incubators.